Search

Your search keyword '"De Vleeschauwer, Annebel R."' showing total 11 results
Start Over Author "De Vleeschauwer, Annebel R."
11 results on '"De Vleeschauwer, Annebel R."'

6. Complete Genome Sequences of Four Foot-and-Mouth Disease Viruses of Serotype South African Territories 1 (SAT 1), Topotype X, Isolated from Cattle in Nigeria in 2015

Author

Vandenbussche, Frank, primary, Mathijs, Elisabeth, additional, Ularamu, Hussaini G., additional, Ehizibolo, David O., additional, Haegeman, Andy, additional, Lefebvre, David, additional, Lazarus, David D., additional, Wungak, Yiltawe S., additional, De Vleeschauwer, Annebel R., additional, Van Borm, Steven, additional, and De Clercq, Kris, additional

Published
2017
Full Text
View/download PDF

10. Efficacy of an AS03A-adjuvanted split H5N1 influenza vaccine against an antigenically distinct low pathogenic H5N1 virus in pigs

Author

De Vleeschauwer, Annebel R., Baras, Benoît, Kyriakis, Constantinos S., Jacob, Valérie, Planty, Camille, Giannini, Sandra L., Mossman, Sally, and Van Reeth, Kristien

Subjects
*DRUG efficacy, *IMMUNOLOGICAL adjuvants, *H5N1 Influenza, *EPITOPES, *LABORATORY swine, *NEURAMINIDASE, *BLOOD agglutination, *IMMUNOGLOBULINS
Abstract

Abstract: We used the pig model of influenza to examine the efficacy of an AS03A-adjuvanted split H5N1 (A/Indonesia/05/2005) vaccine against challenge with a low pathogenic (LP) H5N1 avian influenza (AI) virus (duck/Minnesota/1525/1981) with only 85% amino acid homology in its HA1. Influenza seronegative pigs were vaccinated twice intramuscularly with adjuvanted vaccine at 3 antigen doses, unadjuvanted vaccine or placebo. All pigs were challenged 4 weeks after the second vaccination and euthanized 2 days later. After 2 vaccinations, all pigs in the adjuvanted vaccine groups had high hemagglutination inhibiting (HI) antibody titers to the vaccine strain (160–640), and lower antibody titers to the A/Vietnam/1194/04 H5N1 strain and to 2 LP H5 viruses with 90–91% amino acid homology to the vaccine strain (20–160). Eight out of 12 pigs had HI titers (10–20) to the challenge virus immediately before challenge. Neuraminidase inhibiting antibodies to the challenge virus were detected in most pigs (7/12) and virus neutralizing antibodies in all pigs. There was no antigen-dose dependent effect on the antibody response among the pigs immunized with adjuvanted H5N1 vaccines. After challenge, these pigs showed a complete clinical protection, reduced lung lesions and a significant protection against virus replication in the respiratory tract. Though the challenge virus showed only moderate replication efficiency in pigs, our study suggests that AS03A-adjuvanted H5N1 vaccine may confer a broader protection than generally assumed. The pros and cons of the pig as an H5N1 challenge model are also discussed. [Copyright &y& Elsevier]

Published
2012
Full Text
View/download PDF

11. A canine adenovirus type 2 vaccine vector confers protection against foot-and-mouth disease in guinea pigs

Author

Charly Pignon, Labib Bakkali-Kassimi, Bernard Klonjkowski, David J. Lefebvre, Annebel De Vleeschauwer, Annabelle Garnier, Sandrine A. Lacour, Kris De Clercq, Stéphan Zientara, Fleur Watier, Xiaocui Zhou, Sciensano [Bruxelles], Réseau International des Instituts Pasteur (RIIP), Institut National de la Recherche Agronomique (INRA), China Animal Health and Epidemiology Center, Virologie UMR1161 (VIRO), Institut National de la Recherche Agronomique (INRA)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-École nationale vétérinaire d'Alfort (ENVA), École nationale vétérinaire d'Alfort (ENVA), Belgian Federal Public Service for Health, Food Chain Safety and Environment [RI14/2-26], French Agence Nationale de la Recherche [ANR-14-ANWA-0007-01], European Project: 226556,EC:FP7:KBBE,FP7-KBBE-2008-2B,FMD-DISCONVAC(2009), De Vleeschauwer, Annebel R., Zhou, Xiaocui, Klonjkowski, Bernard, École nationale vétérinaire - Alfort (ENVA)-Institut National de la Recherche Agronomique (INRA)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), and École nationale vétérinaire - Alfort (ENVA)

Subjects
0301 basic medicine, Male, viruses, [SDV]Life Sciences [q-bio], Genetic Vectors, Guinea Pigs, Marker vaccine, Biology, Adenoviruses, Canine, Cross Reactions, Antibodies, Viral, FMDV, 03 medical and health sciences, Mice, 0302 clinical medicine, Immune system, Dogs, Immunogenicity, Vaccine, Antigen, medicine, Animals, 030212 general & internal medicine, Vector (molecular biology), Foot-and-mouth disease, Vaccines, Synthetic, General Veterinary, General Immunology and Microbiology, Vaccination, Public Health, Environmental and Occupational Health, virus diseases, biochemical phenomena, metabolism, and nutrition, medicine.disease, Virology, 3. Good health, Canine adenovirus type 2 (CAV2), 030104 developmental biology, Infectious Diseases, Capsid, Immunization, Foot-and-Mouth Disease Virus, cardiovascular system, Molecular Medicine, Female
Abstract

International audience; Vaccination is a key element in the control of foot-and-mouth disease (FMD). The majority of the antigenic sites that induce protective immune responses are localized on the FMD virus (FMDV) capsid that is formed by four virus-encoded structural proteins, VP1 to VP4. In the present study, recombinant canine adenovirus type 2 (CAV2)-based FMD vaccines, Cav-Pl/3C R degrees and Cav-VP1 R degrees, respectively expressing the structural P1 precursor protein along with the non-structural 3C protein or expressing the structural VP1 protein of the FMDV strain O/FRA/1/2001, were evaluated as novel vaccines against FMD. A strong humoral immune response was elicited in guinea pigs (GP) following immunization with Cav-P1/3C R, while administration of Cav-VP1 R degrees did not induce a satisfying antibody response in GP or mice. GP were then used as an experimental model for the determination of the protection afforded by the Cav/P1 R degrees vaccine against challenge with the FMDV strain O-1 Manisa/Turkey/1969. The Cav-P1/3C R vaccine protected GP from generalized FMD to a similar extent as a high potency double-oil emulsion O-1 Manisa vaccine. The results of the present study show that CAV2-based vector vaccines can express immunogenic FMDV antigens and offer protection against generalized FMD in GP. This suggest that Cav-P1 R FMDV vaccine may protect natural host species from FMD. In combination with an appropriate diagnostic test, the Cav-P1 R degrees FMDV vaccine may also serve as a marker vaccine to differentiate vaccinated from infected animals.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results